Business Context and Reporting Period
This Form 8-K was filed by Inmed Pharmaceuticals Inc. on June 17, 2022. The company is incorporated in British Columbia, Canada, and its common shares trade on The Nasdaq Capital Market under the symbol "INM". The filing addresses a specific regulatory notice regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the company's stock price performance relative to listing requirements rather than operational financial results.
Material Changes
The primary material event reported is the receipt of a written notice from Nasdaq on June 17, 2022. The notice states that the average closing bid price of the company's common shares fell below the minimum $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2) over a period of 30 consecutive trading days.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted a 180-calendar-day grace period to cure the deficiency and regain compliance.
- Trading Status: The notice has no immediate impact on the listing; shares will continue to trade on Nasdaq under the symbol "INM" subject to other listing requirements.
- Management Action: Management intends to monitor the closing share price and explore available options to regain compliance.
- Risks and Contingencies: If the company fails to evidence compliance within the 180-day period, Nasdaq is expected to notify the company that its shares are subject to delisting. The company may appeal such a determination to a Nasdaq Hearings Panel, but there is no assurance that an appeal would be successful or that an extension would be granted.
Investor Verification Checklist
- Verify the current closing bid price of INM shares to assess progress toward the $1.00 threshold.
- Monitor for any subsequent filings regarding a reverse stock split or other corporate actions intended to cure the deficiency.
- Track the 180-day compliance deadline to determine the risk of potential delisting.
- Review the company's most recent 10-K or 10-Q for underlying financial health, as this 8-K does not contain operational financial data.